Veidlapa Nr. M-3 (8)
Study Course Description
Acute Leukemia and Myelodysplastic Syndromes
Course Code
RHE_032
Branch of Science
Clinical medicine
ECTS
9.00
Target Audience
Medicine
LQF
Level 8
Study Course Implementer
Course Supervisor
Sandra Lejniece
Residency Speciality
Speciality
Hematologist
Supervisor of Medical Speciality
Sandra Lejniece
Contacts
-
About Study Course
Objective
-
Learning Outcomes
Knowledge
1.-
Skills
1.-
Competences
1.-
Assessment
Individual work
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Individual work |
-
|
-
|
Examination
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Examination |
-
|
-
|
Study Course Theme Plan
FULL-TIME
Part 1
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
-
|
Total ECTS (Creditpoints):
9.00
Number of Residency Seminars:
6
Length (weeks):
8
Final Examination:
Residency exam (Theory and practice)
Bibliography
Required Reading
1.
M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska & C. Buske, on behalf of the ESMO Guidelines Committee. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upy. Published in 2020 – Ann Oncol (2020); 31(0): 697-712.
2.
D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. M. Ribera, C. Buske on behalf of the ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 27 (Supplement 5): v69–v82, 2016 doi:10.1093/annonc/mdw025
3.
NCCN Clinical Practice Guidelines in Oncology. Myelodisplastic syndromes. Version 1.2020.- August27, 2019.
4.
Guillermo Montalban-Bravo,| Guillermo Garcia-Manero .Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:129–147
5.
P. Fenaux, D. Haase, G. F. Sanz, V. Santini, C. Buske on behalf of the ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 25 (Supplement 3): iii57–iii69, 2014 doi:10.1093/annonc/mdu180
6.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
7.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544
8.
Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672.
9.
S.Lejniece. Klīniskā hematoloģija. Medicīnas Apgāds, 2020.
10.
Klīnisko analīžu rokasgrāmata. E.Gulbja laboratorija. Izdevējs E.Gulbja laboratorija, 2019.
11.
Alla Rivkina. Plūsmas citometrijas metode hematoloģisko slimību diagnostikā. SIA Medicīnas apgāds, 2019